Arthur L Brody1,2, Daniel Gehlbach3,4, Lizette Y Garcia3,4, Ryutaro Enoki3,4, Carl Hoh5, David Vera5, Kishore K Kotta5, Edythe D London6,7, Kyoji Okita6,7,8, Erika L Nurmi6, Lauren C Seaman6, Mark A Mandelkern9. 1. Department of Psychiatry, University of California, San Diego/VA San Diego Healthcare System, San Diego, CA, USA. abrody@ucsd.edu. 2. Department of Research, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA, 92161, USA. abrody@ucsd.edu. 3. Department of Psychiatry, University of California, San Diego/VA San Diego Healthcare System, San Diego, CA, USA. 4. Department of Research, VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA, 92161, USA. 5. Department of Radiology, University of California, San Diego, San Diego, CA, USA. 6. Department of Psychiatry, University of California at Los Angeles, Los Angeles, CA, USA. 7. Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 8. Department of Clinical Neuroimaging, Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, Tokyo, Japan. 9. Nuclear Medicine Service, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Abstract
RATIONALE: Microglia are the main immune cells in the central nervous system and participate in neuroinflammation. When activated, microglia express increased levels of the translocator protein 18 kDa (TSPO), thereby making TSPO availability a marker for neuroinflammation. Using positron emission tomography (PET) scanning, our group recently demonstrated that smokers in the satiated state had 16.8% less binding of the radiotracer [11C]DAA1106 (a radioligand for TSPO) in the brain than nonsmokers. OBJECTIVES: We sought to determine the effect of overnight smoking abstinence on [11C]DAA1106 binding in the brain. METHODS: Forty participants (22 smokers and 18 nonsmokers) completed the study (at one of two sites) and had usable data, which included images from a dynamic [11C]DAA1106 PET scanning session (with smokers having been abstinent for 17.9 ± 2.3 h) and a blood sample for TSPO genotyping. Whole brain standardized uptake values (SUVs) were determined, and analysis of variance was performed, with group (overnight abstinent smoker vs. nonsmoker), site, and TSPO genotype as factors, thereby controlling for site and genotype. RESULTS: Overnight abstinent smokers had lower whole brain SUVs (by 15.5 and 17.0% for the two study sites) than nonsmokers (ANCOVA, P = 0.004). The groups did not significantly differ in injected radiotracer dose or body weight, which were used to calculate SUV. CONCLUSIONS: These results in overnight abstinent smokers are similar to those in satiated smokers, indicating that chronic cigarette smoking leads to global impairment of microglial activation which persists into early abstinence. Other explanations for study results, such as smoking leading to reduced numbers of microglia or smokers having more rapid metabolism of the radiotracer than nonsmokers, are also possible.
RATIONALE: Microglia are the main immune cells in the central nervous system and participate in neuroinflammation. When activated, microglia express increased levels of the translocator protein 18 kDa (TSPO), thereby making TSPO availability a marker for neuroinflammation. Using positron emission tomography (PET) scanning, our group recently demonstrated that smokers in the satiated state had 16.8% less binding of the radiotracer [11C]DAA1106 (a radioligand for TSPO) in the brain than nonsmokers. OBJECTIVES: We sought to determine the effect of overnight smoking abstinence on [11C]DAA1106 binding in the brain. METHODS: Forty participants (22 smokers and 18 nonsmokers) completed the study (at one of two sites) and had usable data, which included images from a dynamic [11C]DAA1106 PET scanning session (with smokers having been abstinent for 17.9 ± 2.3 h) and a blood sample for TSPO genotyping. Whole brain standardized uptake values (SUVs) were determined, and analysis of variance was performed, with group (overnight abstinent smoker vs. nonsmoker), site, and TSPO genotype as factors, thereby controlling for site and genotype. RESULTS: Overnight abstinent smokers had lower whole brain SUVs (by 15.5 and 17.0% for the two study sites) than nonsmokers (ANCOVA, P = 0.004). The groups did not significantly differ in injected radiotracer dose or body weight, which were used to calculate SUV. CONCLUSIONS: These results in overnight abstinent smokers are similar to those in satiated smokers, indicating that chronic cigarette smoking leads to global impairment of microglial activation which persists into early abstinence. Other explanations for study results, such as smoking leading to reduced numbers of microglia or smokers having more rapid metabolism of the radiotracer than nonsmokers, are also possible.
Authors: R B Gonçalves; R D Coletta; K G Silvério; L Benevides; M Z Casati; J S da Silva; F H Nociti Journal: Inflamm Res Date: 2011-02-05 Impact factor: 4.575
Authors: Andrea Varrone; Vesa Oikonen; Anton Forsberg; Juho Joutsa; Akihiro Takano; Olof Solin; Merja Haaparanta-Solin; Sangram Nag; Ryuji Nakao; Nabil Al-Tawil; Lisa A Wells; Eugenii A Rabiner; Ray Valencia; Marcus Schultze-Mosgau; Andrea Thiele; Sonja Vollmer; Thomas Dyrks; Lutz Lehmann; Tobias Heinrich; Anja Hoffmann; Agneta Nordberg; Christer Halldin; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-21 Impact factor: 9.236
Authors: Rajesh Narendran; Brian J Lopresti; Neale Scott Mason; Lora Deuitch; Jennifer Paris; Michael L Himes; Chowdari V Kodavali; Vishwajit L Nimgaonkar Journal: J Neurosci Date: 2014-07-23 Impact factor: 6.167
Authors: Bartholomeus C M 'Benno' Haarman; Huibert Burger; Janine Doorduin; Remco J Renken; Anita J Sibeijn-Kuiper; Jan-Bernard C Marsman; Erik F J de Vries; Jan Cees de Groot; Hemmo A Drexhage; Richard Mendes; Willem A Nolen; Rixt F Riemersma-Van der Lek Journal: Brain Behav Immun Date: 2015-09-05 Impact factor: 7.217
Authors: Alessandro Colasanti; Qi Guo; Paolo Giannetti; Matthew B Wall; Rexford D Newbould; Courtney Bishop; Mayca Onega; Richard Nicholas; Olga Ciccarelli; Paolo A Muraro; Omar Malik; David R Owen; Allan H Young; Roger N Gunn; Paola Piccini; Paul M Matthews; Eugenii A Rabiner Journal: Biol Psychiatry Date: 2015-12-05 Impact factor: 13.382
Authors: Sjoerd T T Schetters; Diego Gomez-Nicola; Juan J Garcia-Vallejo; Yvette Van Kooyk Journal: Front Immunol Date: 2018-01-25 Impact factor: 7.561
Authors: Ansel T Hillmer; David Matuskey; Yiyun Huang; Nabeel Nabulsi; Jim Ropchan; Richard E Carson; Stephanie S O'Malley; Kelly P Cosgrove Journal: J Nucl Med Date: 2020-01-31 Impact factor: 10.057
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare Journal: J Neuroimmune Pharmacol Date: 2019-12-13 Impact factor: 4.147
Authors: Gausiha Rathitharan; Jennifer Truong; Junchao Tong; Tina McCluskey; Jeffrey H Meyer; Romina Mizrahi; Jerry Warsh; Pablo Rusjan; James L Kennedy; Sylvain Houle; Stephen J Kish; Isabelle Boileau Journal: Addict Biol Date: 2020-02-04 Impact factor: 4.280
Authors: Edythe D London; Kyoji Okita; Kaitlin R Kinney; Andrew C Dean; Megan N McClintick; Elizabeth J Rizor; Maritza C Johnson; Tarannom Mahmoudie; Arthur L Brody; Erika L Nurmi; Lauren C Seaman; Judah Farahi; Nathaniel Ginder; Mark A Mandelkern Journal: Drug Alcohol Depend Date: 2020-06-11 Impact factor: 4.852
Authors: Lingling Zhang; Kuan Hu; Tuo Shao; Lu Hou; Shaojuan Zhang; Weijian Ye; Lee Josephson; Jeffrey H Meyer; Ming-Rong Zhang; Neil Vasdev; Jinghao Wang; Hao Xu; Lu Wang; Steven H Liang Journal: Acta Pharm Sin B Date: 2020-08-25 Impact factor: 11.413